Galectin Therapeutics Inc (NASDAQ:GALT) shares are jumping almost 18% today on the heels of the drug maker walking into a credit line to …
Roth Capital’s Yasmeen Rahimi still pinpoints almost 30% upside potential for GALT shares following the biotech firm’s failed Phase 2b trial.
H.C.
Galectin Therapeutics Inc (NASDAQ:GALT) is crash-landing 35% to the market floor once investors caught word of the biotech firm’s Phase 2b NASH-CX study …
